Evidence map›Paper›PMID 38386480›Full record

ArticleMovement disorders clinical practice2024

Spatiotemporal Gait Differences before and after Botulinum Toxin in People with Focal Dystonia: A Pilot Study.

Justine Cuinat, Bettina Debû, Sara Meoni, Pierre Pelissier, Anna Castrioto, Valérie Fraix, Elena Moro

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Movement disorders clinical practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03938363 (Analyse de la Marche de Patients Atteints de Dystonie Focale Avant et après Traitement Par Toxine Botulique), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03938363 nacompletednot on this map

Analyse de la Marche de Patients Atteints de Dystonie Focale Avant et après Traitement Par Toxine Botulique

TypeinterventionalSponsorUniversity Hospital, GrenobleRan2019 to 2022Enrolled40ConditionsCervical Dystonia, Primary, BlepharospasmArmsTreadmill, Botulinum Toxin injection, Severity scale of the disease
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Justine CuinatDivision of Neurology, CHU of Grenoble, Grenoble, France.
Bettina DebûUniversity Grenoble Alpes, Grenoble Institute of Neuroscience, INSERM 1216, Grenoble, France.
Sara MeoniDivision of Neurology, CHU of Grenoble, Grenoble, France.ORCID 0000-0003-2995-6762
Pierre PelissierDivision of Neurology, CHU of Grenoble, Grenoble, France.
Anna CastriotoDivision of Neurology, CHU of Grenoble, Grenoble, France.
Valérie FraixDivision of Neurology, CHU of Grenoble, Grenoble, France.ORCID 0000-0003-4473-9993
Elena MoroDivision of Neurology, CHU of Grenoble, Grenoble, France.ORCID 0000-0002-7968-5908
Inserm · FRCentre Hospitalier Universitaire de Grenoble · FR

Funding

IPSEN Fund
6 · The paper itself

Abstract

backgroundThe impact of focal dystonia on gait has attracted little attention and remains elusive. Considering the importance of both visual and head control in gait, blepharospasm and cervical dystonia should affect gait. Improvement of cervical/eyelid control following botulinum toxin (BTX) injections would translate into gait changes.

objectivesTo assess gait differences in people with focal dystonia before and after BTX treatment.

methodsTen patients with blepharospasm, 10 patients with cervical dystonia, and 20 healthy age- and gender-matched controls were included. Gait was assessed before and 1-month after BTX injections using Biodex Gait Trainer™ 3. Gait velocity, cadence, step length, step asymmetry, and variability of step length were compared between patients and controls, and between the two time-points using non-parametric statistics.

resultsAt baseline, compared to controls, cervical dystonia patients showed reduced gait velocity, step length, and cadence. After BTX injections, while gait velocity and step length were significantly increased and step length variability reduced, gait parameters still differed between patients and controls. In blepharospasm patients, baseline gait velocity and step length were significantly smaller than in controls. After BTX injections, these gait parameters were significantly increased and variability decreased, so that patients no longer differed from controls.

conclusionGait differences exist between patients with focal dystonia not directly affecting the lower limbs and healthy controls. These gait abnormalities were improved differently by BTX treatment according to the type of dystonia. These disparities suggest different pathophysiological mechanisms and support the need for changes in rehabilitation routines in cervical dystonia.

Indexed as

BlepharospasmBotulinum ToxinsDystonic DisordersTorticollisGaitHumansPilot ProjectsBotulinum Toxinsblepharospambotulinum toxincervical dystoniadystoniagait

Identifiers

PMID38386480
PMCPMC10883397
OpenAlexW4389489638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.